Physician profile
Reena J Salgia
NPI 1528180601
$111,890.69
in general payments reported to CMS, 2019-2025
21 companies · $14K in 2025
The $14K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $21K · 2021: $14K · 2022: $19K · 2023: $11K · 2024: $5,669 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Consulting Fee: $4,162 · Food and Beverage: $920 · Grant: $188 · Travel and Lodging: $33.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,292.50 |
| Consulting Fee | $4,161.75 |
| Food and Beverage | $920.29 |
| Grant | $187.50 |
| Travel and Lodging | $33.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $35,163.25 | 2019-2023 | |
| Exelixis INC. | $18,319.24 | 2019-2022 | |
| Gilead Sciences, INC. | $15,669.03 | 2020-2025 | Vemlidy |
| E.R. Squibb & Sons, L.L.C. | $13,950.04 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $10,726.28 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $5,900.00 | 2020-2023 | Xifaxan |
| Cook Incorporated | $5,700.00 | 2025 | Echotip Insight |
| Genentech USA, INC. | $3,579.71 | 2020-2021 | |
| Wilson Cook Medical Incorporated | $1,250.00 | 2024 | Echotip Insight |
| Celgene Corporation | $600.00 | 2022 | |
| Cook Medical LLC | $417.82 | 2021-2025 | Echotip Insight, Echotip |
| Ardelyx, INC. | $187.50 | 2024 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $122.88 | 2019 | |
| Boston Scientific Corporation | $118.39 | 2023 | |
| Biocompatibles, INC. | $104.93 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $81.62 | 2024 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Salgia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.